CEO, Cameron Reynolds discusses with Andrew Scott positive interim results from Danish colorectal cancer study

Cameron Reynolds speaking about Volition's Assay Development Program

An interview with Cameron Reynolds - 2019 Highlights, Octamer Acquisition and Look Ahead to 2020

Volition Announces Strategic Acquisition

VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

Volition Announces Proof of Concept Data in Lymphoma and Leukemia

Proactive Interview with Cameron Reynolds, President & CEO

Third Quarter 2019 Results & Business Update - an interview with Cameron Reynolds

Signing Ceremony with interviews from members of the Volition and Texas A&M Teams

Proactive Investor Interview Quarter Two Earnings Update